Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository (Q37307609)

19 August 2017

Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository (English)

1 reference

19 August 2017

Lisa F Newcomb

1

1 reference

19 August 2017

James D Brooks

2

1 reference

19 August 2017

Peter R Carroll

3

1 reference

19 August 2017

Ziding Feng

4

1 reference

19 August 2017

Martin E Gleave

5

1 reference

19 August 2017

Peter S Nelson

6

1 reference

19 August 2017

Ian M Thompson

7

1 reference

19 August 2017

Daniel W Lin

8

1 reference

19 August 2017

language of work or name

English

0 references

publication date

16 September 2009

1 reference

19 August 2017

1 reference

19 August 2017

75

1 reference

19 August 2017

2

1 reference

19 August 2017

407-413

1 reference

Screening and prostate-cancer mortality in a randomized European study

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Mortality results from a randomized prostate-cancer screening trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Fusion in the ETS gene family and prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Active surveillance for early-stage prostate cancer: review of the current literature

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

6 September 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Quantifying the role of PSA screening in the US prostate cancer mortality decline

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Active surveillance with selective radical treatment for localized prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Contemporary trends in low risk prostate cancer: risk assessment and treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Guideline for the management of clinically localized prostate cancer: 2007 update.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

20-year outcomes following conservative management of clinically localized prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Active surveillance: towards a new paradigm in the management of early prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Active surveillance for the management of prostate cancer in a contemporary cohort

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

A web-based system for managing and co-ordinating multiple multisite studies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Active surveillance with selective delayed intervention for favorable risk prostate cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827723

Geographic pathology of latent prostatic carcinoma

3 December 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.050

Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.050

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.050

Understanding and appreciating overdiagnosis in the PSA era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.050

Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.050

Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.050

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.050

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.05.050

7 January 2021

https://pubmed.ncbi.nlm.nih.gov/19758683

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2009.05.050

1 reference

19 August 2017

1 reference

19 August 2017

1 reference